Latest broker research reports for companies in
with sell recommendations along with share price targets forecast and upside.
Browse thousands of reports and search by company.
Standalone EBITDA increased 7.8% YoY to Rs. 4,426cr as production costs fell, byproducts' realisations went up and the prices of input commodities softened. Reported PAT increased 14.5% YoY to Rs. 2,632cr owing to a growth in improved EBITDA and a fall in finance costs. HZL's revenue growth in the quarter was partially offset by a decline in production due to delay in commissioning of Roaster 6, which has impacted the availability of Calcine *over or under performance to benchmark index affecting company's production. Strong private consumption, capital expenditure and favourable government policies have helped create a positive demand environment that is...
Krishna Institute of Medical Sciences (KIMS)’s Q2FY26 revenue was in line with our expectation. That said, EBITDA loss at Maharashtra of INR 96mn (-100bps) and Karnataka of INR 255mn (-265bps) coupled with lower margin at Kerala cluster dragged EBITDA margins to a low of 21.2%.
KPIT reported revenue and EBIT margin in line with our estimates in Q2FY26. Management expects growth to stabilise in Q3 (flat to 1% QoQ CC) and pickup from Q4.
Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.
Hindalco (HNDL)’s Q2FY26 EBITDA, at INR 89.7bn, was 5% better than our estimates driven by Novelis’ stronger performance, while HNDL’s domestic business aligned with our estimates.
NHPC reported a steady Q2FY26, wherein subdued performance in standalone plants was offset by much better performance in subsidiaries. Its consolidated plant availability declined to 78.6% in Q2 (vs 88.9% YoY) impacted by lower availability in standalone plants, especially Parbati II and III.
We maintain REDUCE on Britannia, with a Sep-26E TP of Rs5,750, on 48x P/E (in line with its last 5Y average forward P/E). Q2 net sales grew at ~4%, 1%/4% below our estimate/consensus expectation.
Novelis’ (Hindalco’s 100% subsidiary) Q2FY26 (adj.) EBITDA of USD 422mn (and ~USD 448/te) was 4% better than our estimates due to lower-than-expected impact of the Oswego fire accident.
Whirlpool of India (Whirlpool) reported weak quarter with revenue decline of 3.8% YoY due to high base of Q2FY25, likely high inventory at beginning of the quarter and demand softness in summer products.
Near-term profitability is likely to remain constrained by elevated input costs and subdued pricing in key regions. Nonetheless, a post-monsoon recovery in demand, improving plant utilization, and commissioning of new capacities are expected to support a gradual earnings rebound.
SAIL’s Q2FY26 reported EBITDA, at INR 25.2bn, was 23% better than our estimates, driven by higher sales volumes, better by-product sales and operating leverage.
Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.
MMFS reported a steady quarter, with PAT at ~Rs5.7bn (+8% QoQ/+54% YoY), ahead of Street and our estimates. Credit costs remained elevated at 2.2% (vs 1.9% in Q1), though the management expects moderation in coming quarters with full-year levels contained at ~1.7%.
GODIGIT delivered a largely in-line performance during Q2FY26, with combined ratio at 111.4% (down by 70bps YoY) vs our estimate of 111%. However, PAT at Rs1.17bn (+30% YoY) was lower than our estimate of Rs1.2bn.
Per media reports, the Supreme Court (SC) has permitted the Centre to reconsider the issue of reassessment for Vodafone Idea (VI)’s AGR dues. This allows the government (GoI) to grant significant relief on AGR dues to VI.
The 2QFY26 margin performance of Dr Reddy’s was marginally weaker than our expectations (in line with street estimates; adjusted for one-offs), with the gross margin (GM) decline being sharper than our expectations (at 55%, GM logged at its lowest since the launch of gRevlimid) and largely a consequence of lower-than-expected gRevlimid sales.
SBI Cards (SBIC) has been focusing on credit cost improvement and the results are becoming visible now. However, this has also led to a calibrated credit growth and directionally lower revolver mix, impacting earnings.
